DB
KYMR icon

Dmitry Balyasny’s Kymera Therapeutics KYMR Stock Holding History

Dmitry Balyasny’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22,677
Closed -$577K – 2891
2023
Q4 		$577K Buy
+22,677
New +$406K ﹤0.01% 1891
2023
Q3 		– Sell
-52,043
Closed -$1.2M – 2513
2023
Q2 		$1.2M Buy
+52,043
New +$1.49M ﹤0.01% 1551
2021
Q3 		– Sell
-119,761
Closed -$5.81M – 2196
2021
Q2 		$5.81M Buy
119,761
+55,451
+86% +$2.41M 0.03% 664
2021
Q1 		$2.5M Buy
+64,310
New +$3.87M 0.01% 949

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Dmitry Balyasny's KYMR Position: Q1 2024 in Review

Dmitry Balyasny sold out of Kymera Therapeutics (KYMR) in Q1 2024, closing a stake of 22,677 shares — an estimated $577K sold.

Dmitry Balyasny first reported a position in KYMR in Q1 2021 and held it in 4 quarters. The position peaked at $5.81M in Q2 2021. 164 funds tracked by Wall St. Rank hold KYMR as of Q1 2024.

  • Dmitry Balyasny reported no remaining Kymera Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Dmitry Balyasny sold 22,677 Kymera Therapeutics shares in Q1 2024, an estimated $577K.
  • Dmitry Balyasny first reported a position in Kymera Therapeutics in Q1 2021 and held it in 4 quarters.
  • Dmitry Balyasny's Kymera Therapeutics position peaked at $5.81M in Q2 2021.
  • 164 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2024.

Based on Balyasny Asset Management's 13F filing for Q1 2024, filed 13 May 2024.